Therapeutic effect and prognosis of interferon therapy after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma associated with hepatitis B virus / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 460-462, 2004.
Article
in Chinese
| WPRIM
| ID: wpr-250195
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the therapeutic effect of interferon therapy after transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma associated with hepatitis B virus.</p><p><b>METHODS</b>Sixty-two patients with advanced primary hepatocellular carcinoma associated with hepatitis B virus was randomly divided into 2 groups. Thirty-one cases were treated with TACE and Interferon. Thirty-one cases with TACE only. HBV DNA, clinical effect, intrahepatic tumor recurrence rate and survival rate were studied.</p><p><b>RESULTS</b>Of the 31 patients in TACE+IFN group, 17 (54.8%) were negative for HBV DNA at the end of treatment. None of TACE group was negative for HBV DNA. The intrahepatic tumor recurrence rate at 1 year and 2 years in TACE+IFN group was 16.1%, 29.0%, compared with 38.7%, 61.3% in TACE group (chi-square = 3.97, chi-square 6.51, P < 0.05). The survival rate in the former was 83.9% and 74.2% respectively, compared with that of 61.3% and 38.7% in the latter (chi-square = 3.97, chi-square = 7.94, P < 0.05).</p><p><b>CONCLUSION</b>Interferon therapy after transcatheter arterial chemoembolization resulted low recurrence and long survival in patients with hepatocellular carcinoma associated with hepatitis B virus. This method showed fewer side effects and should be recommended.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Therapeutics
/
Epidemiology
/
Survival Rate
/
Mortality
/
Interferon-alpha
/
Chemoembolization, Therapeutic
/
Combined Modality Therapy
/
Therapeutic Uses
/
Hepatitis B
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Hepatology
Year:
2004
Type:
Article
Similar
MEDLINE
...
LILACS
LIS